The process of leukemogenesis

Environmental Health Perspectives

Volumn 104, Issue SUPPL. 6, 1996, Pages 1239-1246

  Irons, Richard D ^a   Stillman, Wayne S ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Acute myelogenous leukemia; Benzene; Leukemogenesis; Myelodysplastic syndrome

Indexed keywords

ALKYLATING AGENT; BENZENE;

ACUTE GRANULOCYTIC LEUKEMIA; CARCINOGENESIS; CHROMOSOME ABERRATION; CONFERENCE PAPER; HEMATOPOIETIC STEM CELL; LEUKEMOGENESIS; PRIORITY JOURNAL; STEM CELL;

EID: 0030460982     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.961041239     Document Type: Conference Paper

References (122)

1. Foucar K, McKenna RW, Bloomfield CD, Bowers TK, Brunning RD. Therapy-related leukemia. Cancer 43:1285-1296 (1979).
2. Foulds L. Neoplastic Development. New York:Academic Press, 1969.
3. Foulds L. The experimental study of tumor progression: a review. Cancer Res 14:327-339 (1954).
4. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304:596-602 (1983).
5. Willman CL, Whittaker MH. The molecular biology of acute myeloid leukemia. Proto-oncogene expression and function in normal and neoplastic myeloid cells. Clin Lab Med 10:769-796 (1990).
6. Varmus H, Weinberg RA. Genes and the Biology of Cancer. New York:Scientific American Library, 1993.
7. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 319(9):525-532 (1988).
8. Leary AG, Zeng HQ, Clark SC, Ogawa M. Growth factor requirements for survival in GO and entry into the cell cycle of primitive human hemopoietic progenitors. Proc Natl Acad Sci USA 89:4013-4017 (1992).
9. Ikebuchi K, Clark SC, Ihle JN, Souza LM, Ogawa M. Granulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA 85:3445-3449 (1988).
10. Ogawa M, Matsuzaki Y, Nishikawa S, Hayashi S-I, Kunisada T, Sudo T, Kina T, Nakauchi H, Nishikawa S-I. Expression and function of c-kit in hemopoietic progenitor cells. J Exp Med 174:63-71 (1991).
11. d mice as a single factor. Blood 79:913-919 (1992).
12. Gibson FM, Bagnara M, Ioannidou E, Gordon-Smith EC. Interaction of granulocyte-macrophage colony-stimulating factor and interleukin-3 in human long-term bone marrow culture. Exp Hematol 20:235-240 (1992).
13. Leary GA, Yang YC, Clark SC, Gasson JC, Golde DW, Ogawa M. Recombinant gibbon interleukin-3 supports formation of human multilineage colonies and blast cell colonies in culture: comparision with recombinant human granulocyte-macrophage colony-stimulating factor. Blood 70:1343-1348 (1987).
14. Tsunoda J-I, Okada S, Suda J, Nagayoshi K, Nakauchi H, Hatake K, Miura Y, Suda T. In vivo stem cell function of interleukin-3-induced blast cells. Blood 78:318-322 (1991).
15. Wood PMD, Jordan RK, Givan AL, Brooks CG. IL-3 and IL-4 affect thymocyte differentiation in organ culture. Immunology 71:83-89 (1990).
16. Soloff RS, Dempsey D, Jennings SR, Wolcott RM, Chervenak R. Characterization of the progeny of pre-T cells maintained in vitro by IL-3: appearance in the periphery and Vb utilization in vivo. Cell Immunol 135:132-142 (1991).
17. Koike K, Ogawa M, Ihle JN, Miyake T, Shimizu T, Miyajima A, Yokota T, Arai K-I. Recombinant murine granulocytemacrophage (GM) colony-stimulating factor supports formation of GM and multipotential blast cell colonies in culture: comparison with the effects of interleukin-3. J Cell Physiol 131:458-464 (1987).
18. Chang JM, Metcalf D, Lang RA, Gonda TJ, Johnson GR. Nonneoplastic hematopoietic myeloprolifetative syndrome induced by dysregulated multi-CSF (IL-3) expression. Blood 73:1487-1497 (1989).
19. Lang RA, Metcalf D, Gough NM, Dunn AR, Gonda TJ. Expression of a hemopoietic growth factor cDNA in a factor-dependent cell line results in autonomous growth and tumorigenicity. Cell 43:531-542 (1985).
20. Stocking C, Loliger C, Kawai M, Suciu S, Gough N, Ostertag W. Identification of genes involved in growth autonomy of hematopoietic cells by analysis of factor-independent mutants. Cell 53:869-879 (1988).
21. Young KM. Myeloproliferative disorders. Vet Clin N Am: Small Anim Prac 15:769-781 (1985).
22. Dempster AM, Snyder CA. Short term benzene exposure provides a growth advantage for granulopoietic progenitor cells over erythroid progenitor cells. Arch Toxicol 64:539-544 (1990).
23. Farris GM, Everitt JI, Irons RD, Popp JA. Carcinogenicity of inhaled benzene in CBA mice. Fundam Appl Toxicol 20:503-507 (1993).
24. Cronkite EP, Drew RT, Inoue T, Hirabayashi Y, Bullis JE. Hematotoxicity and carcinogenicity of inhaled benzene. Environ Health Perspect 82:97-108 (1989).
25. Irons RD, Stillman WS, Colagiovanni DB, Henry VA. Synergistic action of the benzene metabolite hydroquinone on myelopoietic stimulating activity of granulocyte/macrophage colony-stimulating factor in vitro. Proc Natl Acad Sci USA 89:3691-3695 (1992).
26. Irons RD, Stillman WS. Cell proliferation and differentiation in chemical leukemogenesis. Stem Cells 11:235-242 (1993).
27. Irons RD, Stillman WS. Impact of benzene metabolites on differentiation of bone marrow progenitor cells. In: Benzene '95: International Conference on the Toxicity, Carcinogenesis, and Epidemiology of Benzene, 17-20 July 1995, Piscataway, NJ. Abstract.
28. Layton DM, Mufti GJ. Myelodysplastic syndromes: their history, evolution and relation to acute myeloid leukaemia. Blut 53:423-436 (1986).
29. Casciato DA, Scott JL. Acute leukemia following prolonged cytotoxic agent therapy. Medicine 58(1):32-47 (1979).
30. Anderson RL, Bagby GC Jr, Richert-Boe K, Magenis RE, Koler RD. Therapy-related preleukemic syndrome. Cancer 47:1867-1871 (1981).
31. Coltman CA, Dahlberg S. Treatment-related leukemia. N Engl J Med 322:52-53 (1990).
32. Advani SH, Doval DC, Gopal R, Nair CN, Kutty PM. Therapy-related leukemia. Oncology 40:268-272 (1983).
33. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199 (1982).
34. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103:626-629 (1985).
35. Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 19(1):47-84 (1992).
36. Allan WSA. Acute myeloid leukaemia after treatment with cytostatic agents. Lancet October 10:775 (1970).
37. Bartolucci AA, Liu C, Durant JR, Gams RA. Acute myelogenous leukemia as a second malignant neoplasm following the successful treatment of advanced Hodgkin's disease. Cancer 52:2209-2213 (1983).
38. Boivin J-F, Hutchison GB. Leukemia and other cancers after radiotherapy and chemotherapy for Hodgkin's disease. J Natl Cancer Inst 67 (4):751-760 (1981).
39. Coleman CN, Williams CJ, Flint A, Glatstein EJ, Rosenberg SA, Kaplan HS. Hematologic neoplasia in patients treated for Hodgkin's disease. N EnglJ Med 297:1249-1252 (1977).
40. Devereux S. Therapy associated leukaemia. Blood Rev 5:138-145 (1991).
41. Greene MH, Harris EL, Gershenson DM, Malkasian GD Jr, Melton LJ III, Dembo AJ, Bennett JM, Moloney WC, Boice JD Jr. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med 105:360-367 (1986).
42. Grunwald HW, Rosner F. Acute myeloid leukemia following treatment of Hodgkin's disease: a review. Cancer 50:676-683 (1982).
43. Grunwald HW, Rosner F. Acute leukemia and immunosuppressive drug use: a review of patients undergoing immunosuppressive therapy for non-neoplastic diseases. Arch Intern Med 139:461-466 (1979).
44. Hoppe RT. Secondary leukemia and myelodysplastic syndrome after treatment for Hodgkin's disease. Leukemia 6 (Suppl 4):155-157 (1992).
45. Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 14(12):1748-1757 (1986).
46. Kyle RA, Gertz MA. Second malignancies after chemotherapy. In: The Chemotherapy Source Book (Perry MC, ed). Baltimore:Williams & Wilkins, 1992; 689-702.
47. Kyle RA. Second malignancies associated with chemotherapeutic agents. Semin Oncol 9(1):131-142 (1982).
48. Lishner M, Slingerland J, Barr J, Panzarella T, Degendorfer P, Sutcliffe S. Second malignant neoplasms in patients with non-Hodgkin's lymphoma. Hematol Oncol 9:169-179 (1991).
49. Pedersen-Bjergaard J, Larsen SO. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med 307:965-971 (1982).
50. Pedersen-Bjergaard J. Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review, Leuk Res 16:61-65 (1992).
51. Pedersen-Bjergaard J, Nissen NI, Sorensen HM, Hou-Jensen K, Larsen MS, Ernst P, Ersbol J, Knudtzon S, Rose C. Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with treosulfan (=dihydroxybusulfan). Cancer 45:19-29 (1980).
52. Rosner F, Grunwald HW. Hodgkin's disease and acute leukemia: report of eight cases and review of the literature. Am J Med 58:339-353 (1975).
53. Rosner F, Grunwald HW. Multiple myeloma terminating in acute leukemia. Am J Med 57:927-939 (1974).
54. Kaldor JM, Day NE, Pettersson F, Clarke EA, Pedersen D, Mehnert W, Bell J, Host H, Prior P, Karjalainen S, Neal F, Koch M, Band P, Choi W, Kirn VT, Arslan A, Zaren B, Belch AR, Storm H, Kittelmann B, Fraser P, Stovall M. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 322:1-6 (1990).
55. Smit CGS, Meyler L. Acute myeloid leukaemia after treatment with cytostatic agents. Lancet September 26:671-672 (1970).
56. Trump DL, Cowall DE. Acute myelogenous leukemia as a late complication of the multimodality therapy for Hodgkin's disease. Johns Hopkins Med J 141:249-251 (1977).
57. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318(2):76-81 (1988).
58. Mitelman F, Nilsson PG, Brandt L, Alimena G, Gastaldi R, Dallapiccola B, Chromosome pattern, occupation, and clinical features in patients with acute nonlymphocytic leukemia. Cancer Genet Cytogenet 4:197-214 (1981).
59. Mitelman F, Brandt L, Nilsson PG. Relation among occupational exposure to potential mutagenic/carcinogenic agents, clinical findings, and bone marrow chromosomes in acute nonlymphocytic leukemia. Blood 52:1229-1237 (1978).
60. Golomb HM, Alimena G, Rowley JD, Vardiman JW, Testa JR, Sovik C. Correlation of occupation and karyotype in adults with acute nonlymphocytic leukemia. Blood 60:404-411 (1982).
61. Fagioli F, Cuneo A, Piva N, Carli MG, Previati R, Balboni M, Tomasi P, Cariani D, Scapoli G, Castoldi G. Distinct cytogenetic and clinicopathologic features in acute myeloid leukemia after occupational exposure to pesticides and organic solvents. Cancer 70:77-85 (1992).
62. Crane MM, Keaing MJ, Trujillo JM, Labarthe DR, Frankowski RF. Environmental exposures in cytogenetically defined subsets of acute nonlymphocytic leukemia. JAMA 262:634-6639 (1989).
63. Narod SA, Dube ID. Occupational history and involvement of chromosomes 5 and 7 in acute nonlymphocytic leukemia. Cancer Genet Cytogenet 38:261-269 (1989).
64. Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 65(6): 1364-1372 (1985).
65. Cuneo A, Fagioli F, Pazzi I, Tallarico A, Previati R, Piva N, Carli GM, Balboni M, Castoldi G. Morphologic, immunologic and cytogenetic studies in acute myeloid leukemia following occupational exposure to pesticides and organic solvents. Leuk Res 16:789-796 (1992).
66. Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 83:3780-3786 (1994).
67. Aksoy M. Benzene Carcinogenicity. Boca Raton, FL:CRC Press, 1988.
68. Vigliani EC, Forni A. Benzene and leukemia. Environ Res 11:122-127 (1976).
69. Forni A, Vigliani EC. Chemical leukemogenesis in man. Semin Hematol 7(2):211-223 (1974).
70. Decoufle P, Blattner WA, Blair A. Mortality among chemical workers exposed to benzene and other agents. Environ Res 30:16-25 (1983). Abstract.
71. Rowley JD, Golomb HM, Vardiman J. Nonrandom chromosomal abnormalities in acute nonlymphocytic leukemia in patients treated for Hodgkins disease and non-Hodgkins lymphomas. Blood 50:759-770 (1977).
72. Rowley JD, Golomb HM, Vandiman JW. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood 58:759-767 (1981).
73. Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM, Rowley JD. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 4(3):325-345 (1986).
74. Pedersen-Bjergaard J, Philip P, Perdersen NT, Hou-Jensen K, Svejgaard A, Jensen G, Nissen NL Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. Cancer 54:452-462 (1984).
75. Johansson B, Mertens F, Heim S, Kristoffersson U, Mitelman F. Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL). Eur J Haematol 47:17-27 (1991).
76. Bitter MA, Le Beau MM, Rowley JD, Larson RA, Golomb HM, Vardiman JW. Associations between morphology, karyorype, and clinical features in myeloid leukemias. Hum Pathol 18:211-225 (1987).
77. Fourth International Workshop on Chromosomes in Leukemia 1982. The correlation of karyotype and occupational exposure to potential mutagenic/carcinogenic agents in acute nonlymphocytic leukemia. Cancer Genet Cytogenet 11:326-331 (1984).
78. Bloomfield CD, Goldman A, Hossfeld D, de la Chapelle A. Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet Cytogenet 11:332-350 (1984).
79. Pedersen-Bjergaard J, Philip P, Mortensen BT, Ersboll J, Jensen G, Panduro J, Thomsen M. Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. Clinical and cytogenetic characteristics and results of in vitro culture of bone marrow and HLA typing. Blood 57(4):712-723 (1981).
80. Smith MT, Zhang L, Rothman N, Wang Y, Hayes RB, Li GL, Yin SN. Interphase cytogenetics of workers exposed to benzene. Toxicologist 15:87 (1995).Abstract.
81. Van den Berghe H, Louwagie A, Broeckaert-Van Orshoven A, David G, Verwilghen R. Chromosome analysis in two unusual malignant blood disorders presumably induced by benzene. Blood 53:558-566 (1979).
82. Zhang L, Rothman N, Wang Y, Hayes RB, Yin S-N, Holland N, Dosemeci M, Wang Y-Z, Kolachana P, Xi L-Q, Li G-L, Smith MT. Aneuploidy of chromosomes 7, 8 and 9 detected by fluorescence in situ hybridization in workers exposed to benzene. Proc Natl Acad Sci USA 92:4069-4073 (1995). (Abstract).
83. Le Beau MM, Rowley JD. Chromosomal abnormalities in leukemia and lymphoma: clinical and biological significance. Adv Hum Genet 15:1-54 (1986).
84. Stone R, Neuberg D, Soiffer R, Whelan M, Leavitt P, Aster J, Takvorian R, Rabinowe S, Ritz J, Freedman A, Nadler L. Myelodysplastic syndrome (MDS) as a complication after autologous bone marrow transplantation (ABMT) for non Hodgkin's lymphoma (NHL). Blood 82:196a (1993). Abstract.
85. Chen HW, Frantz C, Eastmond DA, Inhibition of topoisomerase enzymes by phenolic metabolites: a potential mechanism for benzene's clastogenic effects. In: Benzene '95: International Conference on the Toxicity, Carcinogenesis, and Epidemiology of Benzene, 17-20 July 1995, Piscataway, NJ. Abstract.
86. Luna-Fineman S, Shannon KM, Lange BJ. Childhood monosomy 7: epidemiology, biology, and mechanistic implications. Blood 85:1985-1999 (1995).
87. van den Berghe H, Vermaelen K, Mecucci C, Barbieri D, Tricot G. The 5q- anomaly. Cancer Genet Cytogenet 17:189-225 (1985).
88. Rowley JD, Le Beau MM. Cytogenetic and molecular analysis of therapy-related leukemia. Ann NY Acad Sci 567:130-140 (1989).
89. Murphree AL, Benedict WF. Retinoblastoma: clues to human oncogenesis. Science 223:1028-1033 (1984).
90. Nimer SD, Golde DW. The 5q- abnormality. Blood 70:1705-1712 (1987).
91. Ridge SA, Worwood M, Oscier D, Jacobs A, Padua RA. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci USA 87:1377-1380 (1990).
92. Radich JP, Kopecky KJ, Appelbaum F, Willman CL, Collins SJ. N-ras mutations in acute myelogenous leukemia: a review of the current literature and an update of the Southwest Oncology Group experience. Leuk Lymphoma 6:325-334 (1992).
93. Liu ET. The role of ras gene mutations in myeloproliferative disorders. Clin Lab Med 10:797-807 (1990).
94. Kastan MB, Strauss LC, Civin CI. The role of hematopoietic growth factors and oncogenes in leukemogenesis. Am J Pediatr Hematol Oncol 11:249-267 (1989).
95. Needleman SW. Ras protooncogene activation in acute myeloid leukemia and related disorders. Leuk Lymphoma 5:85-91 (1991).
96. Taylor JA, Sandier DP, Bloomfield CD, Shore DL, Ball ED, Neubauer A, McIntyre OR, Liu E. Ras oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst 84:1626-1632 (1992).
97. Kubo K, Naoe T, Kiyoi H, Fukutani H, Kato Y, Oguri T, Yamamori S, Akatsuka Y, Kodera Y, Ohno R. Clonal analysis of multiple point mutations in the N-ras gene in patients with acute myeloid leukemia. Jpn J Cancer Res 84:379-387 (1993).
98. Hirai H, Okada M, Mizoguchi H, Mano H, Kobayashi Y, Nishida J, Takaku F. Relationship between an activated N-ras oncogene and chromosomal abnormality during leukemic progression from myelodysplastic syndrome. Blood 71:256-258 (1988).
99. Toksoz D, Farr CJ, Marshall CJ. Ras gene activation in a minor proportion of the blast population in acute myeloid leukemia. Oncogene 1:409-413 (1987).
100. Farr CJ, Saiki RK, Erlich HA, McCormick F, Marshall CJ. Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc Natl Acad Sci USA 85:1629-1633 (1988).
101. Chen C-Y, Oliner JD, Zhan Q, Fornace AJ Jr, Vogelstein B, Kastan MB. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 91:2684-2688 (1994).
102. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 Mutations in human cancers. Science 253:49-53 (1991).
103. Soussi T, Jonveaux P. p53 Gene alterations in human hematological malignancies: a review, Nouv Rev Fr Hematol 33:477-480 (1991).
104. Knudson AG. Hereditary cancers disclose a class of cancer genes. Cancer 63:1888-1891 (1989).
105. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 81:323-330 (1995).
106. Kornblau S, Xu H-J, del Giglio A, Hu S-X, Zhang W, Calvert L, Beran M, Estey E, Andreeff M, Trujillo J, Cork MA, Smith TL, Benedict WF, Deisseroth AB. Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia. Cancer Res 52:4587-4590 (1992).
107. Furukawa Y, DeCaprio JA, Belvin M, Griffin JD. Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells. Oncogene 6:1343-1346 (1991).
108. Bagby GC, Wilkinson B, McCall E, Lee M. Abnormalities of the hematopoietic regulatory network. Adv Exp Med Biol 241:255-264 (1988).
109. Foon KA, Champlin RE, Gale RP. Acute myelogenous leukemia and the myelodysplastic syndromes. In: Cancer Treatment (Haskell CM, ed). Philadelphia:W.B. Saunders, 1990; 589-606.
110. + acute leukemia. Blood 86:60-65 (1995).
111. + cells. Blood 85:194-202 (1995).
112. Kroef MJPL, Fibbe WE, Mout R, Jansen RPM, Haak HL, Wessels JW, Van Kamp H, Willemze R, Landegent JE. Myeloid but not lymphoid cells carry the 5q deletion: polymerase chain reaction analysis of loss of heterozygosity using mini-repeat sequences on highly purified cell fractions. Blood 81:1849-1854 (1993).
113. Young DC, Wagner K, Griffin JD. Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia. J Clin Invest 79:100-106 (1987).
114. Zwierzina H, Schöllenberger S, Herold M, Schmalzl F, Besemer J. Endogenous serum levels and surface receptor expression of GM-CSF and IL-3 in patients with myelodysplastic syndromes. Leuk Res 16:1181-1186 (1992).
115. Coutinho LH, Geary CG, Chang J, Harrison C, Testa NG. Functional studies of bone marrow haemopoietic and stromal cells in the myelodysplastic syndrome (MDS). Br J Haematol 75:16-25 (1990).
116. Greenberg BR, Wilson FD, Woo L. Granulopoietic effects of human bone marrow fibroblastic cells and abnormalities in the "granulopoietic microenvironment." Blood 58:557-564 (1981).
117. Sachs L, Lotem J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood 82:15-21 (1993).
118. Raza A, Mundle S, Iftikhar A, Gregory S, Marcus B, Khan Z, Alvi S, Shetty V, Dameron S, Wright V, Adler S, Loew JM, Shott S, Ali SN, Preisler H. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol 48:143-154 (1995).
119. Raza A, Gezer S, Mundle S, Gao X-Z, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86:268-276 (1995).
120. Pech N, Hermine O, Goldwasser E. Further study of internal autocrine regulation of multipotent hematopoietic cells. Blood 82:1502-1506 (1993).
121. Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K. Chromosome aberrations and prognostic factors in therapyrelated myelodysplasia and acute nonlymphocytic leukemia. Blood 76:1083-1091 (1990).
122. Wald N, Conner MK. Induced chromosome damage after irradiation and cytotoxic drugs. Hematology 8:159-201 (1988).